Bladder cancer patients get a second chance with their own immune cells
NCT ID NCT05768347
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new way to treat high-grade bladder cancer that hasn't spread into the muscle. Doctors take immune cells from the patient's own tumor, grow them in a lab, and put them back into the bladder. The goal is to see if this is safe and can shrink or eliminate the cancer. Only 9 people who have already tried BCG therapy will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-INVASIVE BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- Leftover urine may predict bladder cancer recurrence